Related by context. All words. (Click for frequent words.) 68 Scale PANSS 68 NIH CPSI 67 PANSS 67 Brief Psychiatric 66 Global Impression CGI 66 Negative Syndrome 66 ADCS ADL 66 Montgomery Åsberg Depression 66 WOMAC pain 66 BMI z 65 Rating Scale MADRS 65 ADAS cog 65 Symptom Checklist 65 subscales 65 UPDRS 65 Montgomery Asberg Depression 65 Alzheimer Disease Assessment 64 Brief Pain 64 HAQ DI 64 Global Impression 64 HADS 64 Health Assessment Questionnaire 64 ADAS Cog 64 subscale scores 63 HDRS 63 HRQL 62 Fibromyalgia Impact Questionnaire 62 YMRS 62 SGRQ 62 PANSS total 62 Ocular Surface Disease 62 subscore 62 Severity Index PASI 62 PANSS scores 62 affective psychosis 61 EQ 5D 61 Negative Symptoms 61 IRLS 61 subscores 61 PSQI 61 Y BOCS 61 Severity Index 61 ADCS CGIC 61 Symptom severity 61 HAM D# 61 Visual Analog 61 nasal symptom 61 QoL 60 Rating Scale 60 erection hardness 60 IBDQ 60 depressive symptom 60 comorbid anxiety 60 Rating Scale BPRS 60 Hamilton Rating Scale 60 Main Outcome Measures 60 HAMD 60 Psoriasis Area 60 Status Scale EDSS 60 BPRS 60 Distress Scale 59 HRQoL 59 CHADS2 59 HRQOL 59 Crohn Disease Activity 59 symptom severity 59 Visual Analog Scale 59 HOMA IR 59 State Examination MMSE 59 DLQI 59 State Trait Anxiety 59 MMSE 59 DAS# scores 59 interobserver 59 MMSE score 59 Neuropsychiatric Inventory NPI 58 Clinically meaningful 58 posttest 58 MADRS 58 exploratory endpoints 58 convergent validity 58 meta analytic 58 liver histology 58 MADRS score 58 Visual Analogue Scale VAS 58 depressive symptomatology 58 biopsy Gleason 58 Secondary endpoints included 58 Geriatric Depression 58 Primary endpoints 58 Comorbidity 58 BPH symptom 58 UPDRS motor 58 cognitive affective 58 Outcome Measures 58 State Exam MMSE 58 WOMAC scores 58 PERMP 58 WAIS III 58 Unified Parkinson Disease 57 Clinician Administered PTSD 57 UPDRS Part III 57 pain subscale 57 Seattle Angina Questionnaire 57 PANSS Positive 57 Pharmacodynamic 57 Visual Analogue Scale 57 psychosocial variables 57 EORTC QLQ C# 57 Heritability 57 NYHA functional class 57 glycosylated hemoglobin levels 57 QIDS SR 57 Outcomes Study 57 Dyspnea 57 Index CDAI 57 CI -#.# 57 alexithymia 57 CORE OM 57 Depression Inventory 57 premorbid 57 Scale Cognitive Subscale 57 Mental Component 57 Functioning GAF 57 WOMAC 57 urodynamic parameters 57 psychosocial functioning 57 Pain Intensity 57 demonstrated clinically meaningful 57 SF #v# 57 Depression Scale 57 Neurocognitive 57 GERD symptom 56 HAM D 56 Inventory BPI 56 CPAP adherence 56 neurocognitive function 56 Wechsler Adult 56 Depressive Symptoms 56 Cronbach alpha 56 albumin excretion rate 56 Functional Assessment 56 salivary cortisol 56 SELENA SLEDAI 56 euthymic patients 56 Histologic 56 NIS LL 56 CNS LS 56 ADHD RS 56 ADHD Rating Scale 56 erythrocyte sedimentation rate 56 Depression Scale HADS 56 Erectile Function 56 interrater reliability 56 SSRI citalopram 56 Neuropsychological 56 meta regression 56 CIBIC plus 56 Depressive Symptomatology 56 FACIT Fatigue 56 NWEA MAP 56 Ishak fibrosis score 56 Retreatment 56 subjective sleepiness 56 CIBIC + 56 Hopkins Symptom Checklist 56 generalized estimating 56 MMSE scores 56 Abnormal Involuntary Movement 56 glycosylated hemoglobin HbA1c 56 neuropsychological 56 STAI 56 psychometric properties 56 Scale cognitive subscale 56 Rating Scale UPDRS 56 Physical Component 55 IRLS score 55 thyrotropin levels 55 multivariate Cox 55 p = .# [002] 55 Beck Anxiety Inventory 55 serum cortisol 55 International Prostate Symptom 55 Comorbidities 55 HbA1C levels 55 PHQ 9 55 ejaculatory function 55 ANCOVA 55 MoxDuo TM IR 55 posttreatment 55 Severity MSCS score 55 insulin resistance HOMA IR 55 Oswestry Disability Index 55 ALSFRS R 55 Functional Outcomes 55 APACHE II 55 baseline PASI 55 euthymic 55 NIHSS score 55 IPSS 55 orthostatic blood 55 CFQ R 55 subtests 55 bronchial hyperresponsiveness 55 psychoeducation 55 somatic symptoms 55 Score DAS 55 NIHSS 55 attain statistical significance 55 odds ratios ORs 55 Alzheimer Disease Cooperative 55 CDAI score 55 affective disorders 55 Likert 55 Lower Limb 55 left ventricular diastolic 55 KOOS 55 Fasting plasma glucose 55 KCCQ 55 CDAI 55 daytime somnolence 55 psychiatric comorbidity 55 OSDI 55 mRS 55 Disease Activity 55 pharmacodynamic parameters 55 Score IPSS 55 hematologic parameters 55 Child Behavior Checklist 55 Bioavailability 55 ACR# ACR# 55 clinically meaningful improvement 55 Cronbach 55 achieved statistical significance 55 certolizumab 55 IIEF 55 Showed Significant 54 Assessment Questionnaire 54 prolactin elevation 54 psychiatric morbidity 54 Neuropsychological Status 54 multivariable adjusted 54 non menstrual pelvic 54 Acute Physiology 54 Cognitive Function 54 Treatment Outcome 54 Visual acuity 54 Assessment Scale 54 rhinoconjunctivitis 54 Cystic Fibrosis Questionnaire Revised 54 pulmonary capillary wedge 54 nondepressed 54 unpaired t 54 Severity Scale 54 HbA 1c 54 Symptom Score 54 Pain Rating Scale 54 β = 54 DAS# CRP 54 hepatic enzyme 54 DQI 54 Global Impression Severity 54 symptomatology 54 semiquantitative 54 Erectile Function IIEF 54 comorbid depression 54 fructosamine 54 emotional lability 54 Secondary endpoints include 54 haematologic 54 Impressions Improvement 54 desvenlafaxine succinate 54 Scale EDSS 54 TNSS 54 albumin excretion 54 Glasgow Coma Scale 54 neurocognitive functioning 54 mean ± SEM 54 preoperative PSA 54 postintervention 54 plasma leptin 54 poststroke 54 ALS Functional 54 subsyndromal 54 sociodemographic characteristics 54 Stroke Scale 54 fasting insulin 54 guanfacine extended release 54 bivariate analyzes 54 hip BMD 54 PASI scores 54 antidepressant monotherapy 54 hemodynamic measurements 54 PCWP 54 multivariable analysis 54 covariance ANCOVA 53 Sociodemographic 53 Preoperatively 53 cognitive domains 53 SSRI SNRI 53 ANOVA 53 HbA 1c levels 53 echocardiographic parameters 53 confirmed CCyR 53 cardiac autonomic 53 univariate analyzes 53 carotid artery intima media 53 nerve conduction velocity 53 Score DAS# 53 amnestic mild cognitive impairment 53 suicide attempters 53 Stroke Scale NIHSS 53 F FDG PET 53 syndromal 53 nonsignificant 53 function subscale 53 VFQ 53 diabetes mellitus DM 53 -#.# mg dL [001] 53 extrapyramidal symptoms 53 retest reliability 53 Depressive symptoms 53 Expanded Disability Status 53 UPDRS scores 53 anthropometric measures 53 daytime alertness 53 Depression Rating Scale 53 urinary N telopeptide 53 Maslach Burnout Inventory 53 subthreshold depression 53 Depression Inventory BDI 53 schizophrenia schizoaffective disorder 53 postinjury 53 multiple linear regression 53 Mini Mental 53 moderate renal impairment 53 schizophreniform disorder 53 Charlson comorbidity index 53 Secondary efficacy endpoints 53 Histological 53 peak VO2 53 nonsignificant difference 53 hemodynamic parameters 53 covariate 53 BILAG 53 Repeatable Battery 53 MDRD 53 mTSS 53 Functional Capacity 53 Respiratory Symptoms 53 Diagnostic Criteria 53 episodic migraine 53 Wakefulness Test 53 Ashworth Scale 53 mg BID dose 53 % Confidence Interval 53 EDSS scores 53 extrapyramidal side 53 subsyndromal depression 53 epoetin alpha 53 Clinical Dementia 53 enthesitis 53 fractional anisotropy 53 Score TOS 53 apolipoprotein B 53 Mania Rating Scale 53 cortical atrophy 53 hemoglobin A1c levels 53 tapentadol ER 53 Pharmacologic 52 multiple logistic regression 52 lowest tertile 52 autonomic dysfunction 52 intact parathyroid hormone 52 multivariate regression 52 Risk Stratification 52 Generalized Anxiety Disorder 52 Univariate 52 transcranial Doppler ultrasound 52 brachial artery flow 52 Echocardiographic 52 AUA BPH Symptom Score 52 urodynamic 52 #.#/#.# mmHg [001] 52 Cockcroft Gault 52 Subscale 52 serum lipid 52 electrophysiologic 52 pharmacological therapy 52 Edinburgh Postnatal Depression 52 interpersonal psychotherapy 52 clinicopathological 52 posttransplant 52 Female Sexual Function 52 neurobehavioral functioning 52 -#.# ± [002] 52 Severity CGI S 52 neuropsychological assessment 52 Hemoglobin A1c 52 glycosylated hemoglobin 52 serum urate 52 parkinsonian 52 maximal treadmill 52 somatization 52 hypochondriasis 52 Myocardial Perfusion 52 PSA nadir 52 postprocedure 52 GH deficiency 52 logistic regression model 52 NNT = 52 primary aldosteronism 52 nonparametric 52 Timed Walk 52 prospectively stratified 52 Epidemiological Studies Depression 52 affective psychoses 52 chi squared 52 Likert scale 52 audiometric 52 Cholinesterase Inhibitors 52 oxycodone CR 52 Myocardial Infarction TIMI 52 Breslow thickness 52 Mammographic 52 hyperhomocysteinemia 52 Epworth Sleepiness Scale 52 ratio ICER 52 psychophysiological 52 systolic diastolic 52 Symptom Severity 52 Interrater reliability 52 MCID 52 fasting plasma glucose FPG 52 confidence intervals CIs 52 ETDRS 52 covariance 52 Orthostatic Hypotension 52 electroencephalographic 52 Rating Scale IRLS 52 idiopathic Parkinson disease 52 endometrial thickness 52 diastolic pressures 52 Functioning Scale 52 mania hypomania 52 psychiatric comorbidities 52 Kruskal Wallis test 52 T2DM 52 nondiabetic patients 52 attention-deficit/hyperactivity disorder 52 Multivariable 52 Evaluable 52 AUA Symptom Score 52 pharmacodynamic PD 52 secondary efficacy endpoint 52 APOE genotype 52 plasma cortisol 52 DAS# [002] 52 Pearson correlation coefficient 52 P ≤ 52 Index WOMAC 51 Demonstrate Significant 51 Charlson Comorbidity Index 51 Patients Receiving 51 Symptom Scale 51 sociodemographic factors 51 ‰ ¥ 51 Complicated Grief 51 docetaxel pretreated 51 dose atorvastatin 51 Anxiety Depression 51 Hb A1c 51 clinically meaningful improvements 51 neuropsychological deficits 51 interobserver reliability 51 premenopause 51 SGOT 51 clinically meaningful reductions 51 chronic prostatitis chronic 51 prespecified secondary 51 CONCERTA ® 51 Secondary endpoints 51 #q# deletion syndrome 51 tic severity 51 bivariate 51 dichotomized 51 corticosteroid dose 51 intratympanic 51 6MWD 51 intraclass correlation coefficients 51 urine albumin 51 tumor histology 51 methotrexate monotherapy 51 divalproex sodium 51 myocardial viability 51 lumbar spine BMD 51 Rosenberg Self Esteem 51 clinical meaningfulness 51 psychodynamic psychotherapy 51 INVEGA ® 51 venlafaxine XR 51 Skin sterol 51 Wechsler Memory 51 hippocampal volumes 51 aMCI precursor 51 intraobserver 51 Endothelial function 51 Relapsing Remitting Multiple Sclerosis 51 atheroma volume 51 HDL cholesterol triglycerides 51 tertiles 51 CIMZIA TM certolizumab pegol 51 multivariable Cox 51 univariate analysis 51 shorter telomere length 51 ejection fractions 51 carotid IMT 51 Main Outcome Measure 51 induced akathisia 51 correlation coefficients 51 Ejection Fraction 51 Hb A1C 51 prospectively defined 51 metabolic parameters 51 Treatment Diabetic Retinopathy 51 cerebral oxygenation 51 virological response 51 Physical Function 51 somatoform disorders 51 LUTS 51 noncognitive 51 MATRICS 51 comorbid psychiatric 51 MS DRGs 51 SKAMP D 51 intelligence quotient IQ 51 tryptophan depletion 51 spirometric 51 Apolipoprotein B 51 multivariable adjustment 51 hypofractionated radiation 51 Prognostic 51 tic disorders 51 #mg/day [001] 51 psychiatric outpatients 51 interrater 51 subtest 51 leukocyte counts 51 death reinfarction 51 Demonstrated Significant 51 alanine aminotransferase ALT 51 perceptual reasoning 51 anticholinergic agents 51 clomipramine 51 OSAHS 51 comorbid 51 Digit Symbol Substitution 51 intraclass correlation coefficient 51 serum homocysteine 51 depressive symptoms 51 bortezomib refractory 51 sociodemographic variables 51 binary logistic regression 51 untreated psychosis 51 â ‰ ¥ 51 mL/min/#.# m 2 51 Meta analyzes 51 interquartile range IQR 51 NYHA 51 variance ANOVA 51 LDL triglycerides 51 regression coefficient 51 aspartate aminotransferase AST 51 nonobese 51 androgen depletion 51 Incontinence Impact Questionnaire 51 Postoperative 51 arterial thickening 51 neuropsychological assessments 51 antioxidant supplementation 51 psychoeducational 51 undetectable HBV DNA 51 serum lipid levels 51 McGill Pain Questionnaire 51 plasma homocysteine 51 dyspnoea 51 logistic regression analyzes 51 olanzapine LAI 51 neuropsychological tests 51 completely resected 51 methacholine challenge 51 MetS 51 morphometric vertebral fractures 51 univariate 51 serum HBV DNA 51 ASIA Impairment 51 Coronary Artery Bypass Graft 50 CYP#D# inhibitor 50 serum phosphorous 50 FACIT 50 amisulpride 50 oral prednisolone 50 = #.#-#.# 50 serum magnesium 50 limiting generalizability 50 Operative mortality 50 psychomotor 50 subclinical atherosclerosis 50 point Likert scale 50 umol L 50 SDQ 50 highest tertile 50 Electrophysiological 50 symptomatic DVT 50 Cognitive Impairment 50 tipranavir r 50 neurobehavioural 50 VADT 50 sUA 50 achieved ACR# 50 EDSS score 50 nasal polyposis 50 comorbid psychiatric disorders 50 overnight polysomnography 50 EBMT criteria 50 hyper IgE syndrome 50 Glycemic Control 50 % CI #.#-#.# [006] 50 atherogenic dyslipidemia 50 akinesia 50 prespecified 50 interpersonal psychotherapy IPT 50 hemoglobin A1c HbA1c 50 Non Responders 50 WOMAC TM 50 Coronary Artery Calcium 50 neurobehavioral 50 hippocampal volume 50 Key secondary endpoints 50 Tumor Response 50 Psychotic Disorders 50 nonpsychotic 50 serologically active patients 50 FDG-PET/CT 50 endoscopic remission 50 lipid parameters 50 coronary stenosis 50 progression TTP 50 conduction velocity 50 P = .# 50 elevated transaminases 50 HER2 expression 50 concomitant AEDs 50 elevated LDH 50 eNO 50 overt nephropathy 50 bioprosthetic valve 50 methodologic 50 sensory gating 50 unfavorable cytogenetics 50 Chronic Illness Therapy 50 sd = 50 neurosensory 50 % CI #.#-#.# [008] 50 Bonferroni correction 50 r2 = 50 LDL HDL 50 = -#.# 50 Solid Tumors 50 estimated glomerular filtration 50 T2 lesions 50 Descriptive statistics 50 adjunctive placebo 50 -#.# mg dL [002] 50 serum bicarbonate 50 Cardiorespiratory fitness 50 acute mania 50 acute subacute 50 diabetic polyneuropathy 50 OGTT 50 Suboptimal 50 BPS IC 50 Demonstrates Statistically Significant 50 lipid profiles 50 dyssynchrony 50 Polysomnography 50 urinary albumin 50 Endocrine Therapy 50 apnea hypopnea 50 venous thromboembolic disease 50 Scale EDSS score 50 serum triglyceride 50 serum phosphate 50 sociodemographic 50 EEG recordings 50 Cognitive Ability 50 neurologic impairment 50 % CI #.#-#.# [007] 50 neurocognition 50 Index HAQ DI 50 serum folate concentrations 50 multivariate analyzes 50 4mg/kg 50 Kidney Function 50 guideline concordant 50 mild renal insufficiency 50 Lewy bodies DLB 50 Angiographic 50 interobserver agreement 50 histologic subtype 50 CCyR 50 neurodevelopmental outcome 50 dyspareunia 50 glycated hemoglobin 50 intima media thickness IMT 50 plasma pharmacokinetics 50 vitreous haze 50 SELENA SLEDAI score 50 sensitivity specificity 50 lipid elevations 50 neuropsychological functioning 50 nonepileptic seizures 50 PsA 50 ankle brachial 50 Coronary CTA 50 aminotransferase levels 50 Anxiety Scale 50 neurocognitive 50 NPRS 50 biochemical recurrence 50 DCE MRI 50 Platelet counts 50 Pharmacokinetic parameters 50 placebo p = 50 Psychiatric Disorders 50 colorectal adenoma 50 relapsed MM 50 Tasigna prolongs 50 parasitological 50 comorbidity 50 SLEDAI 50 antiepileptics 50 CTEPH 50 cerebral glucose metabolism 50 adenotonsillectomy 50 PLMS 50 HbA1C 50 logistic regression 50 somatic symptom 49 socioeconomic variables 49 serum urate levels 49 apnea hypopnea index 49 polysomnographic 49 oxygen desaturation 49 daytime sleepiness 49 Psychodynamic 49 non affective psychosis 49 cardiorespiratory endurance 49 Diabetic Foot Ulcer 49 intravascular hemolysis 49 plasma folate 49 Hypercholesterolemia 49 Primary Endpoint 49 CLBP 49 histologic findings 49 plasma lipids 49 pairwise comparisons 49 ACR# response 49 Negative Symptom Scale 49 -#.# log# copies mL 49 Renal Insufficiency 49 Urogenital Distress Inventory 49 -#.# log# 49 femoral neck BMD 49 oncologic outcomes 49 fasting serum 49 McMaster Universities Osteoarthritis 49 visceral adiposity 49 Common Terminology Criteria 49 confidence interval #.#-#.# 49 pretest probability 49 lipid lowering agents 49 Sleep Disturbance 49 HBeAg negative patients 49 indicates cardio circulatory 49 metaanalysis 49 creatinine ratio 49 risperidone Risperdal 49 postoperative AF 49 fluoxetine paroxetine 49 comorbid disorders 49 Subjective 49 STRIDE PD 49 leucopenia 49 Kruskal Wallis 49 comorbid diagnoses 49 Autistic Disorder 49 PDSS 49 Glomerular Filtration Rate 49 metabolic syndrome MetS 49 PSADT 49 parkinsonian symptoms 49 weakly correlated 49 extensive metabolizers 49 df = 49 cognitive functioning 49 Fasting glucose 49 QOL 49 systolic function 49 underwent CABG 49 left ventricular systolic 49 Follicular Lymphoma 49 parkinson disease 49 clinicopathological features 49 neurophysiologic 49 VYVANSE demonstrated 49 angiotensin II receptor blockers 49 Socio demographic 49 intima media thickness 49 mmHg diastolic 49 fasting plasma 49 #:#-#,# CrossRef Medline [002] 49 Comorbid 49 metabolite concentrations 49 Desvenlafaxine Succinate 49 Nonspecific 49 undergoing coronary angiography 49 Services #:#-#,# Abstract 49 neuroleptic 49 DAS# remission 49 multivariable analyzes 49 serum PSA 49 5 HTTLPR genotype 49 arterial oxygen saturation 49 decompensated cirrhosis 49 dyslipidaemia 49 Bosentan 49 #,#-# [012] 49 demonstrated statistically significant 49 microvessel density 49 pharmacologic therapies 49 tissue oxygenation 49 prodromal symptoms 49 Methods Retrospective 49 Index FSFI 49 bioavailable testosterone 49 ARB telmisartan 49 moderate hepatic impairment 49 hematological parameters 49 tertile 49 hepatic fat 49 Psychiatric Epidemiology 49 glomerular filtration 49 overactive bladder symptoms 49 Healthy Eating Index 49 Systematic Treatment 49 CRQ 49 Chronic ITP 49 Chronic Renal Failure 49 SEER registries 49 allele frequencies 49 x ULN 49 subscale 49 T1DM 49 daily subcutaneous injections 49 orthostatic 49 hydroxyvitamin D concentrations 49 Hamilton Anxiety Scale 49 anterior temporal 49 alicaforsen enema 49 laboratory abnormalities 49 Posttraumatic 49 Psychomotor 49 psychopathological symptoms 49 β blockers 49 Bayley Scales 49 Regression Analysis 49 Differential Diagnosis 49 Randomized Evaluation 49 LV dysfunction 49 HbA1c levels 49 substance induced psychosis 49 LH FSH 49 Mean Symptom Complex 49 retrospective cohort 49 hemoglobin A1C 49 estimated GFR 49 Exacerbations 49 Non inferiority 49 neuropathological 49 pretreatment serum 49 Metastatic Renal Cell Carcinoma 49 androgen suppression 49 SBM frequency 49 nonpharmacologic 49 blood Phe levels 49 Total Nasal Symptom 49 neuromotor 49 nausea photophobia 49 diffusion tensor 49 statistically significant p = 49 NAA Cr 49 Numeric Rating Scale 49 HbA 1C 49 immunochemical fecal occult 49 amnestic MCI 49 alanine aminotransferase 49 baseline LDH 49 REYATAZ r arm 49 retinal thickness 49 CHADS 49 Subgroup analysis 49 Poisson regression 49 Index CDAI score 49 Univariate analysis 49 Clinician Interview Based 49 Secondary Hyperparathyroidism 49 carotid bruit 49 nonfatal MI 49 Viral load 49 VLBW 49 vitreous floaters 49 neuropsychiatric symptoms 49 glomerular filtration rate 49 percutaneous vertebroplasty 49 antiretroviral naïve 49 induced sputum 49 psychiatric inpatients 49 neutrophil counts 49 prospectively evaluated 49 Atomoxetine 49 Attention-Deficit/Hyperactivity Disorder ADHD 49 Shows Statistically Significant 49 Genant modified Sharp 49 analgesic medications 49 elevated ALT 49 ß = 49 mcg QD 49 ejaculatory control 49 Systematic Review 49 Glomerular filtration rate 49 abnormal cytology 49 plasma lipid 49 baseline A1C 49 Healthy Behavior 49 ± SEM 48 Insulin Glargine 48 adverse cytogenetics 48 Parkinson Disease Rating Scale 48 glycated hemoglobin HbA1c 48 serum triglycerides 48 hip resurfacing arthroplasty 48 paresthesias 48 hematopoietic cancers 48 CAHPS 48 cardiac perfusion 48 mean baseline A1C 48 Sjögren syndrome 48 pharmacological therapies 48 Hyperlipidemia 48 Stable Angina 48 diagnosing ADHD 48 agomelatine 48 ECOG PS 48 conditional logistic regression 48 postop 48 logistic regression analysis 48 histological subtype 48 FDG PET imaging 48 extracapsular extension 48 Correlates 48 Kaplan Meier survival 48 treat NNT 48 elevated fasting glucose 48 medication nonadherence 48 acamprosate calcium 48 multivariate adjustment 48 accelerometry 48 CRp 48 ischemia driven 48 Prefrontal 48 mm Hg diastolic 48 comorbid conditions 48 Self Efficacy 48 N telopeptide 48 Flu Cy 48 postdose 48 et al #a 48 neutropaenia 48 mild cognitive 48 prognostic variables 48 Pharmacodynamics 48 recurrent venous thromboembolism 48 Severity 48 carotid artery narrowing 48 placebo p 48 adenoma detection 48 Polypharmacy 48 FDG uptake